An Open-Label, Parallel, Phase II Study of Single-Agent Oral ESK981 in Men With Castrate-Resistant Prostate Cancer (CRPC)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs CEP 11981 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 18 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 14 Mar 2018 Status changed from not yet recruiting to recruiting.